The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 22, 2025
Filed:
Jan. 22, 2020
Applicant:
Tuojie Biotech (Shanghai) Co., Ltd., Shanghai, CN;
Inventors:
Cuiqing Yang, Shanghai, CN;
Renhong Tang, Shanghai, CN;
Assignee:
Tuojie Biotech (Shanghai) Co., Ltd., Shanghai, CN;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract
The present invention relates to an anti-CD79B antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. Furthermore, the present invention relates to a chimeric antibody and a humanized antibody comprising a CDR region of the anti-CD79B antibody, a pharmaceutical composition comprising the anti-CD79B antibody or the antigen-binding fragment thereof, and a use thereof as an anti-cancer drug. Particularly, the present invention relates to a humanized anti-CD79B antibody, and a use thereof in preparation of a drug for treating lymphoma (such as DLBCL).